CSIMarket
 
Orgenesis Inc   (ORGS)
 
Price: $0.3500 $0.00 0.000%
Day's High: $0.5699999928474426 Week Perf: 970.34 %
Day's Low: $ 0.03 30 Day Perf: 16.67 %
Volume (M): 8,442 52 Wk High: $ 100.00
Volume (M$): $ 0 52 Wk Avg: $28.62
Open: $0.57 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 4
 Employees 77
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 49
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Orgenesis Inc is a Delaware-based biotechnology company that specializes in the development of advanced cell therapy technologies and regenerative medicines. The company primarily focuses on developing and commercializing autologous cell therapies that can be used for treating a range of diseases, including diabetes, liver disease, and other chronic illnesses.

Orgenesis is headquartered in Germantown, Maryland, with offices and subsidiaries in Israel and Belgium. The company was founded by Dr. Dorit Arad and Dr. Sarah Ferber in 2008, and has since expanded its research and development capabilities to become a leading innovator in the field of cell therapy.

The company's core technology is the Orgenesis Diabetes Cell Therapy (ODCT) platform, which uses a patient's own liver cells to produce insulin in response to glucose levels. This novel approach to diabetes treatment has shown promising results in preclinical studies and clinical trials, offering a potential cure for millions of people living with the disease.

In addition to its work in diabetes, Orgenesis is also developing cell therapies for other chronic diseases and conditions, such as liver disease, pancreatitis, and other autoimmune disorders. The company is also collaborating with leading academic and research institutions, such as the University of California, San Francisco, to advance the field of cell therapy and regenerative medicine.

Orgenesis has a strong intellectual property portfolio, with multiple patents and patent applications for its cell therapy technologies. The company is also committed to responsible and sustainable business practices, with a focus on environmental stewardship, ethical standards, and social responsibility.

Overall, Orgenesis Inc is a leading biotechnology company that is at the forefront of developing innovative, patient-centric solutions for chronic diseases and conditions using advanced cell therapy technologies.


   Company Address: 20271 Goldenrod Lane Germantown 20876 MD
   Company Phone Number: 659-6404   Stock Exchange / Ticker: ORGS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TMDX   -4.9%    
• View Complete Report
   



Shares

Orgenesis Completes Reverse Stock Split Amid Positive Milestones in CAR-T Therapy Development

Published Mon, Sep 23 2024 11:00 AM UTC

On September 23, 2024, Orgenesis Inc. (Nasdaq: ORGS), a biotechnology company specializing in cell and gene therapies, announced a strategic move to enhance its stock performance by implementing a 1-for-10 reverse stock split, effective at 5:00 PM Eastern Time on September 24, 2024. This corporate action is aimed at consolidating the number of shares outstanding and increasi...

Clinical Study

Resplendent Triumph Orgenesis ORG-101 CAR-T Therapy Achieves Landmark Success in CD19+ Acute Lymphoblastic Leukemia ...

Published Thu, Aug 29 2024 12:30 PM UTC

Orgenesis Heralds Victorious Results: A Triumph in CAR-T Therapy for CD19+ Acute Lymphoblastic Leukemia Esteemed readers of CSIMarket.com ,In a resplendent display of scientific advancement and medical prowess, Orgenesis Inc. an imperious entity in the biotechnology realm, has announced the prodigious outcomes of its real-world study, concentrating on ORG-101, a CAR-T thera...

Product Service News

Orgenesis and Harley Street Team Up for Revolutionary Global Longevity & Wellness Initiative

Published Wed, Aug 14 2024 12:30 PM UTC

In a groundbreaking announcement that is set to reverberate through the healthcare industry, Orgenesis Inc. has forged a strategic partnership with the esteemed Harley Street Healthcare Group. This alliance aims to launch an innovative global longevity and wellness initiative, reflecting a robust commitment to advancing health and well-being in an era where wellness innovati...

Partnership

Germfree and Orgenesis Partner to Advance Cell and Gene Therapy Production for Global Accessibility

Published Wed, Apr 10 2024 4:00 PM UTC

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership to Revolutionize Cell and Gene TherapyOrmond Beach, Florida, and Germantown, Maryland - Germfree, a leading modular cleanroom infrastructure and services provider, has joined forces with Orgenesis Inc., a global leader in decentralizing cell and gene therapies (CGTs). Through an asset purchase and strat...

Shares

Orgenesis Inc. Secures $2.3 Million Private Placement for Groundbreaking Cell and Gene Therapies

Published Mon, Mar 4 2024 1:30 PM UTC



Orgenesis Inc., a global leader in decentralized cell and gene therapies, recently announced an exciting development in the form of a definitive securities purchase agreement. In this agreement, accredited investors will purchase shares of the company s common stock, along with warrants to purchase additional shares, in a private placement. With expectations of app...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.42
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0
Working Capital Ratio 0.03
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) 3.36

Per Share Current
Earnings (TTM) -2.39 $
Revenues (TTM) 0.25 $
Cash Flow (TTM) -
Cash 0.02 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 13,442
Net Income per Employee (TTM) 636,532
Receivable Turnover Ratio (TTM) 6.03
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.04

Profitability Ratios Current
Gross Margin (MRQ) -3.99 %
Operating Margin (MRQ) 6044.52 %
Net Margin (MRQ) 6769.44 %
Net Cash Flow Margin (MRQ) -135.22 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 212.94 %
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.